{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:55:22Z","timestamp":1793192122738,"version":"4.5.0"},"reference-count":170,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.autrev.2023.103295","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T02:22:05Z","timestamp":1676082125000},"page":"103295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Circulating Calprotectin (cCLP) in autoimmune diseases"],"prefix":"10.1016","volume":"22","author":[{"given":"Mariangela","family":"Manfredi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieve","family":"Van Hoovels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Benucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Coccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edda","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo","family":"Amedei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bossuyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Infantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.autrev.2023.103295_bb0005","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1177\/1535370216681551","article-title":"Calprotectin in rheumatic diseases","volume":"242","author":"Ometto","year":"2017","journal-title":"Exp Biol Med (Maywood)"},{"issue":"6","key":"10.1016\/j.autrev.2023.103295_bb0010","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jbspin.2019.01.003","article-title":"Systemic calprotectin and chronic inflammatory rheumatic diseases","volume":"86","author":"Romand","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2023.103295_bb0015","doi-asserted-by":"crossref","first-page":"1001025","DOI":"10.3389\/fimmu.2022.1001025","article-title":"From bench to bedside: Calprotectin (S100A8\/S100A9) as a biomarker in rheumatoid arthritis","volume":"13","author":"Inciarte-Mundo","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2023.103295_bb0020","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.bbamcr.2006.07.013","article-title":"An update of the S100 nomenclature","volume":"1763","author":"Marenholz","year":"2006","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.autrev.2023.103295_bb0025","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.3390\/ijms13032893","article-title":"Pro-inflammatory S100A8 and S100A9 proteins: self-assembly into multifunctional native and amyloid complexes","volume":"13","author":"Vogl","year":"2012","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1546-0096-11-31","article-title":"Evaluation of anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies in patients with juvenile idiopathic arthritis","volume":"11","author":"Gilliam","year":"2013","journal-title":"Pediatr Rheumatol Online J"},{"issue":"13","key":"10.1016\/j.autrev.2023.103295_bb0035","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1182\/blood-2004-02-0446","article-title":"MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes","volume":"104","author":"Vogl","year":"2004","journal-title":"Blood."},{"issue":"8718","key":"10.1016\/j.autrev.2023.103295_bb0040","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0140-6736(90)93237-J","article-title":"Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin","volume":"336","author":"Steinbakk","year":"1990","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.autrev.2023.103295_bb0045","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1086\/315810","article-title":"Zinc-reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14)","volume":"182","author":"Sohnle","year":"2000","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.autrev.2023.103295_bb0050","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jmb.2007.04.065","article-title":"The crystal structure of the human (S100A8\/S100A9)2 heterotetramer, calprotectin, illustrates how conformational changes of interacting alpha-helices can determine specific association of two EF-hand proteins","volume":"370","author":"Korndorfer","year":"2007","journal-title":"J Mol Biol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103295_bb0055","doi-asserted-by":"crossref","first-page":"M278","DOI":"10.1136\/mp.48.5.M278","article-title":"Calcium binding and concomitant changes in the structure and heat stability of calprotectin (L1 protein)","volume":"48","author":"Naess-Andresen","year":"1995","journal-title":"Clin Mol Pathol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103295_bb0060","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1039\/C5SC03287C","article-title":"Calcium-induced Tetramerization and Zinc Chelation Shield Human Calprotectin from Degradation by Host and Bacterial Extracellular Proteases","volume":"7","author":"Stephan","year":"2016","journal-title":"Chem Sci"},{"issue":"11","key":"10.1016\/j.autrev.2023.103295_bb0065","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2017.09.012","article-title":"Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review","volume":"16","author":"Lee","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcmgh.2021.03.002","article-title":"Neutrophil extracellular traps in inflammatory bowel disease: pathogenic mechanisms and clinical translation","volume":"12","author":"Drury","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"23","key":"10.1016\/j.autrev.2023.103295_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313038","article-title":"An update on the pathogenic role of neutrophils in systemic juvenile idiopathic arthritis and adult-onset still\u2019s disease","volume":"22","author":"Kim","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.autrev.2023.103295_bb0080","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1189\/jlb.5BT0615-247R","article-title":"At the Bench: neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases","volume":"99","author":"Grayson","year":"2016","journal-title":"J Leukoc Biol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103295_bb0085","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nri.2017.105","article-title":"Neutrophil extracellular traps in immunity and disease","volume":"18","author":"Papayannopoulos","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103295_bb0090","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/nm1638","article-title":"Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock","volume":"13","author":"Vogl","year":"2007","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.autrev.2023.103295_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000639","article-title":"Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans","volume":"5","author":"Urban","year":"2009","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/j.autrev.2023.103295_bb0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1189\/jlb.1008647","article-title":"The endogenous Toll-like receptor 4 agonist S100A8\/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer","volume":"86","author":"Ehrchen","year":"2009","journal-title":"J Leukoc Biol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103295_bb0105","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.autrev.2019.06.011","article-title":"An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): implications for the pathogenesis and treatment","volume":"18","author":"Frangou","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2023.103295_bb0110","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nm.2150","article-title":"The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells","volume":"16","author":"Loser","year":"2010","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.autrev.2023.103295_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105671","article-title":"The Involvement of Alarmins in the Pathogenesis of Sjogren\u2019s Syndrome","volume":"23","author":"Sarrand","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.autrev.2023.103295_bb0120","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1161\/CIRCULATIONAHA.110.985523","article-title":"S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: implications for atherosclerosis and adipose tissue inflammation","volume":"123","author":"Averill","year":"2011","journal-title":"Circulation."},{"issue":"8","key":"10.1016\/j.autrev.2023.103295_bb0125","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99276","article-title":"Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus","volume":"3","author":"Carlucci","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/138161211795049741","article-title":"Critical determinants of cardiovascular risk in rheumatoid arthritis","volume":"17","author":"Bisoendial","year":"2011","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.autrev.2023.103295_bb0135","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/CIRCRESAHA.116.309692","article-title":"Neutrophil extracellular traps in atherosclerosis and atherothrombosis","volume":"120","author":"Doring","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.autrev.2023.103295_bb0140","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-2840-5-6","article-title":"Increased proinflammatory endothelial response to S100A8\/A9 after preactivation through advanced glycation end products","volume":"5","author":"Ehlermann","year":"2006","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.autrev.2023.103295_bb0150","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2018.06.817","article-title":"Plasma calprotectin and risk of cardiovascular disease: findings from the PREVEND prospective cohort study","volume":"275","author":"Kunutsor","year":"2018","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.autrev.2023.103295_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102400","article-title":"The etiology of rheumatoid arthritis","volume":"110","author":"Scherer","year":"2020","journal-title":"J Autoimmun"},{"issue":"9","key":"10.1016\/j.autrev.2023.103295_bb0160","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2023.103295_bb0145","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1002\/art.39656","article-title":"Platelet-Derived S100A8\/A9 and cardiovascular disease in systemic lupus erythematosus","volume":"68","author":"Lood","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103295_bb0165","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/rheumatology\/ket315","article-title":"IL-22\/IL-22R1 axis and S100A8\/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts","volume":"52","author":"Carrion","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0170","first-page":"59","article-title":"A longitudinal study of calprotectin as an inflammatory marker in patients with reactive arthritis","volume":"13","author":"Hammer","year":"1995","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103295_bb0175","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3899\/jrheum.140628","article-title":"Calprotectin as a biomarker for rheumatoid arthritis: a systematic review","volume":"42","author":"Abildtrup","year":"2015","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103295_bb0180","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/00325481.2017.1319729","article-title":"Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis","volume":"129","author":"Bae","year":"2017","journal-title":"Postgrad Med"},{"issue":"8","key":"10.1016\/j.autrev.2023.103295_bb0185","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/ard.2006.064741","article-title":"Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis","volume":"66","author":"Hammer","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2023.103295_bb0190","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1136\/annrheumdis-2017-211695","article-title":"Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis","volume":"76","author":"Jonsson","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2023.103295_bb0195","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1136\/annrheumdis-2017-212816","article-title":"Calprotectin is not independent from baseline erosion in predicting radiological progression in early rheumatoid arthritis. Comment on \u2018Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis\u2019 by Jonsson et al","volume":"77","author":"Chevreau","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103295_bb0200","first-page":"859","article-title":"Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity","volume":"19","author":"Brun","year":"1992","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40291-013-0016-9","article-title":"Calprotectin in rheumatoid arthritis\u202f: association with disease activity in a cross-sectional and a longitudinal cohort","volume":"17","author":"Garcia-Arias","year":"2013","journal-title":"Mol Diagn Ther"},{"issue":"2","key":"10.1016\/j.autrev.2023.103295_bb0210","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar2645","article-title":"Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis","volume":"11","author":"Chen","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0215","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/ard.2008.103739","article-title":"Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis","volume":"69","author":"Hammer","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2023.103295_bb0220","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/annrheumdis-2016-210275","article-title":"Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis","volume":"76","author":"Schieir","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2023.103295_bb0225","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2013-203923","article-title":"MRP8\/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis","volume":"74","author":"Choi","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13075-016-1201-0","article-title":"Calprotectin (S100A8\/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis","volume":"19","author":"Nordal","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.autrev.2023.103295_bb0235","doi-asserted-by":"crossref","first-page":"R122","DOI":"10.1186\/ar3426","article-title":"Decreases in serum levels of S100A8\/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis","volume":"13","author":"Andres Cerezo","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0240","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000654","article-title":"Predictive value of serum calprotectin (S100A8\/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis","volume":"4","author":"Tweehuysen","year":"2018","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.autrev.2023.103295_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165498","article-title":"Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission","volume":"11","author":"Hurnakova","year":"2016","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.autrev.2023.103295_bb0250","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s10067-018-4091-5","article-title":"Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein","volume":"37","author":"Hurnakova","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103295_bb0255","first-page":"2239","article-title":"Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants","volume":"54","author":"Inciarte-Mundo","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0260","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-022-02887-7","article-title":"Calprotectin (S100A8\/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy","volume":"24","author":"Gernert","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.autrev.2023.103295_bb0265","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/acr2.11309","article-title":"Combinations of Anticyclic Citrullinated Protein Antibody, Rheumatoid Factor, and Serum Calprotectin Positivity Are Associated With the Diagnosis of Rheumatoid Arthritis Within 3 Years","volume":"3","author":"Bettner","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103295_bb0270","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/rheumatology\/kex081","article-title":"Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time","volume":"56","author":"Baraliakos","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0275","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13075-020-2111-8","article-title":"A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations","volume":"22","author":"Sokolova","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.autrev.2023.103295_bb0280","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/1529-0131(199907)42:7<1481::AID-ANR23>3.0.CO;2-E","article-title":"Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis","volume":"42","author":"Reece","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2023.103295_bb0285","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2015-208025","article-title":"Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis","volume":"75","author":"Cypers","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2020.08.003","article-title":"Serum calprotectin is increased in early axial spondyloarthritis with sacroiliitis and objective signs of inflammation: Results from the DESIR cohort","volume":"88","author":"Romand","year":"2021","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0295","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13075-020-02190-3","article-title":"Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis","volume":"22","author":"Jarlborg","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103295_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106948","article-title":"Calprotectin in spondyloarthritis: a systematic review and meta-analysis","volume":"88","author":"Ma","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103295_bb0305","first-page":"429","article-title":"Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study","volume":"37","author":"Sakellariou","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103295_bb0310","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3899\/jrheum.180432","article-title":"Added Value of Fecal Calprotectin to Support the Diagnosis of Spondyloarthropathies","volume":"46","author":"Vanh","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103295_bb0315","article-title":"Serum Calprotectin level Is independently associated with carotid plaque presence in patients with Psoriatic Arthritis","volume":"9","author":"Cheng","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.autrev.2023.103295_bb0320","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1186\/s13075-014-0413-4","article-title":"Calprotectin (S100A8\/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis","volume":"16","author":"Turina","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.autrev.2023.103295_bb0325","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/rheumatology\/kez025","article-title":"Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis","volume":"58","author":"Rademacher","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2023.103295_bb0330","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00005792-200205000-00003","article-title":"Proposal for a new set of classification criteria for adult-onset still disease","volume":"81","author":"Fautrel","year":"2002","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.autrev.2023.103295_bb0335","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103295_bb0340","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification Criteria for Juvenile Idiopathic Arthritis: first steps, Pediatric Rheumatology International Trials Organization International Consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103295_bb0345","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001646","article-title":"Serum calprotectin (S100A8\/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis","volume":"7","author":"La","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2023.103295_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102793","article-title":"Enhanced type I interferon signature induces neutrophil extracellular traps enriched in mitochondrial DNA in adult-onset Still\u2019s disease","volume":"127","author":"Ma","year":"2022","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.autrev.2023.103295_bb0355","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2011-200598","article-title":"The Toll-like receptor 4 agonist MRP8\/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis","volume":"71","author":"Holzinger","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2023.103295_bb0360","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17081342","article-title":"TLR4 Endogenous Ligand S100A8\/A9 Levels in Adult-Onset Still\u2019s Disease and Their Association with Disease Activity and Clinical Manifestations","volume":"17","author":"Kim","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0365","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12969-020-0398-2","article-title":"The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis","volume":"18","author":"Aljaberi","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"10.1016\/j.autrev.2023.103295_bb0370","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.55563\/clinexprheumatol\/5tckci","article-title":"Serum calprotectin (S100A8\/9), clinical and ultrasound assessment in patients with juvenile idiopathic arthritis","volume":"39","author":"Romano","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0375","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12969-022-00701-x","article-title":"Myeloid-related protein 8\/14 in plasma and serum in patients with new-onset juvenile idiopathic arthritis in real-world setting in a single center","volume":"20","author":"Keskitalo","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"issue":"7","key":"10.1016\/j.autrev.2023.103295_bb0380","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1093\/rheumatology\/keab729","article-title":"MRP8\/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever","volume":"61","author":"Park","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.autrev.2023.103295_bb0385","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1136\/annrheumdis-2012-201329","article-title":"Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study","volume":"71","author":"Gerss","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103295_bb0390","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/acr.22248","article-title":"Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis","volume":"66","author":"Rothmund","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0395","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-015-0723-1","article-title":"MRP8\/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis","volume":"17","author":"Anink","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0400","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"10.1016\/j.autrev.2023.103295_bb0405","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41584-022-00819-y","article-title":"Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management","volume":"18","author":"Trivioli","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0410","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2023.103295_bb0415","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/eci.12410","article-title":"Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis","volume":"45","author":"Kronbichler","year":"2015","journal-title":"Eur J Clin Invest"},{"issue":"8","key":"10.1016\/j.autrev.2023.103295_bb0420","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102716","article-title":"The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis","volume":"20","author":"Guchelaar","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.autrev.2023.103295_bb0430","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","article-title":"Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis","volume":"13","author":"Bossuyt","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0435","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2023.103295_bb0440","article-title":"Serum calprotectin as promising diagnostic aid in predicting relapse in proteinase 3-antineutrophil cytoplasmatic antibodies-associated vasculitis","volume":"2","author":"Van Hoovels","year":"2017","journal-title":"J Lab Precis Med"},{"issue":"6","key":"10.1016\/j.autrev.2023.103295_bb0445","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/ki.2013.2","article-title":"Leukocyte and serum S100A8\/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis","volume":"83","author":"Pepper","year":"2013","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.autrev.2023.103295_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205982","article-title":"Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis","volume":"13","author":"Martinez Valenzuela","year":"2018","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0455","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13075-022-02849-z","article-title":"Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis","volume":"24","author":"Michailidou","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0460","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12865-022-00513-4","article-title":"The potential pathogenic roles of S100A8\/A9 and S100A12 in patients with MPO-ANCA-positive vasculitis","volume":"23","author":"Bai","year":"2022","journal-title":"BMC Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0465","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/art.39814","article-title":"Association of Serum Calprotectin (S100A8\/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"69","author":"Pepper","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103295_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108898","article-title":"Classification of systemic lupus erythematosus in children and adults","volume":"234","author":"Lythgoe","year":"2022","journal-title":"Clin Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103295_bb0475","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2023.103295_bb0480","doi-asserted-by":"crossref","DOI":"10.7326\/AITC202006020","article-title":"Systemic Lupus Erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.autrev.2023.103295_bb0485","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.autrev.2019.05.011","article-title":"The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study","volume":"18","author":"Mageau","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2023.103295_bb0490","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/0961203320979051","article-title":"Systemic lupus erythematosus: the search for the ideal biomarker","volume":"30","author":"Gonzalez","year":"2021","journal-title":"Lupus."},{"issue":"2","key":"10.1016\/j.autrev.2023.103295_bb0495","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001257","article-title":"Urine and serum S100A8\/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment","volume":"6","author":"Davies","year":"2020","journal-title":"RMD Open"},{"issue":"21","key":"10.1016\/j.autrev.2023.103295_bb0500","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1073\/pnas.0909927107","article-title":"Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis","volume":"107","author":"Hakkim","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.autrev.2023.103295_bb0505","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.4049\/jimmunol.1102404","article-title":"Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease","volume":"188","author":"Leffler","year":"2012","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0510","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/096120339300200108","article-title":"Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity","volume":"2","author":"Haga","year":"1993","journal-title":"Lupus."},{"issue":"10","key":"10.1016\/j.autrev.2023.103295_bb0515","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.3899\/jrheum.081302","article-title":"Phagocyte-specific S100A8\/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus","volume":"36","author":"Soyfoo","year":"2009","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0520","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13075-017-1444-4","article-title":"Urine S100 proteins as potential biomarkers of lupus nephritis activity","volume":"19","author":"Turnier","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.autrev.2023.103295_bb0525","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/0961203316655208","article-title":"Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus","volume":"26","author":"Tyden","year":"2017","journal-title":"Lupus."},{"issue":"3","key":"10.1016\/j.autrev.2023.103295_bb0530","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00296-018-4190-2","article-title":"Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study","volume":"39","author":"Sumova","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2023.103295_bb0535","article-title":"S100A8 in Serum, Urine, and Saliva as a Potential Biomarker for Systemic Lupus Erythematosus","volume":"13","author":"Kim","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103295_bb0540","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.936534","article-title":"Serum Calprotectin - a NET Product - as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland","volume":"28","author":"Homa-Mlak","year":"2022","journal-title":"Med Sci Monit"},{"issue":"2","key":"10.1016\/j.autrev.2023.103295_bib843","doi-asserted-by":"crossref","first-page":"000508","DOI":"10.1136\/rmdopen-2017-000508","article-title":"Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus","volume":"3","author":"Tyd\u00e9n","year":"2017","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0545","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"issue":"12","key":"10.1016\/j.autrev.2023.103295_bb0550","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103295_bb0555","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/BOR.0000000000000744","article-title":"Cytokines and inflammatory mediators as promising markers of polymyositis\/dermatomyositis","volume":"32","author":"Cerezo","year":"2020","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103295_bb0560","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar4311","article-title":"Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis","volume":"15","author":"Nistala","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103295_bb0565","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cyto.2018.12.023","article-title":"Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis","volume":"116","author":"Andres Cerezo","year":"2019","journal-title":"Cytokine."},{"issue":"2","key":"10.1016\/j.autrev.2023.103295_bb0570","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/art.41078","article-title":"Neutrophil extracellular traps in tissue and periphery in Juvenile Dermatomyositis","volume":"72","author":"Duvvuri","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2023.103295_bb0575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111490","article-title":"Autophagy, inflammation and innate immunity in inflammatory myopathies","volume":"9","author":"Cappelletti","year":"2014","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0580","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12890-020-01226-3","article-title":"Serum levels of interleukins and S100A8\/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease","volume":"20","author":"Lou","year":"2020","journal-title":"BMC Pulm Med"},{"issue":"10","key":"10.1016\/j.autrev.2023.103295_bb0585","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sjogren\u2019s Syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0590","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sjogren\u2019s syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"10.1016\/j.autrev.2023.103295_bb0595","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312903","article-title":"Salivary Biomarkers in Patients with Sjogren\u2019s Syndrome-A Systematic Review","volume":"22","author":"Jung","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0600","first-page":"129","article-title":"Phagocyte-specific S100A8\/A9 is upregulated in primary Sjogren\u2019s syndrome and triggers the secretion of pro-inflammatory cytokines in vitro","volume":"35","author":"Nicaise","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103295_bb0605","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1600-0722.1997.tb00205.x","article-title":"Indicators of salivary gland inflammation in primary Sjogren\u2019s syndrome","volume":"105","author":"Cuida","year":"1997","journal-title":"Eur J Oral Sci"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0610","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3109\/03009742.2013.848930","article-title":"Calprotectin (S100A8\/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjogren\u2019s syndrome","volume":"43","author":"Nordal","year":"2014","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103295_bb0615","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12016-013-8402-y","article-title":"TLR2 and TLR4 in autoimmune diseases: a comprehensive review","volume":"47","author":"Liu","year":"2014","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103295_bb0620","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/03009740310004775","article-title":"Receptor of advanced glycation end product (RAGE) expression in the minor salivary glands of patients with Sjogren\u2019s syndrome: a preliminary study","volume":"33","author":"Katz","year":"2004","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103295_bb0625","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3109\/03009749409103041","article-title":"Sjogren\u2019s syndrome in inflammatory rheumatic diseases: analysis of the leukocyte protein calprotectin in plasma and saliva","volume":"23","author":"Brun","year":"1994","journal-title":"Scand J Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103295_bb0630","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/jop.12763","article-title":"Salivary S100A8\/A9 in Sjogren\u2019s syndrome accompanied by lymphoma","volume":"47","author":"Jazzar","year":"2018","journal-title":"J Oral Pathol Med"},{"issue":"6","key":"10.1016\/j.autrev.2023.103295_bb0635","first-page":"1006","article-title":"Serum calprotectin is a biomarker of carotid atherosclerosis in patients with primary Sjogren\u2019s syndrome","volume":"34","author":"Balarini","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2023.103295_bb0640","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2023.103295_bb0645","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041706","article-title":"Calprotectin in Lung Diseases","volume":"22","author":"Kotsiou","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2023.103295_bb0650","article-title":"Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application","volume":"5","author":"Damoiseaux","year":"2022","journal-title":"J Transl Autoimmun"},{"issue":"5","key":"10.1016\/j.autrev.2023.103295_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102515","article-title":"Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels","volume":"19","author":"Smeets","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2023.103295_bb0660","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s10067-013-2305-4","article-title":"Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities","volume":"32","author":"Xu","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103295_bb0665","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1136\/annrheumdis-2013-205013","article-title":"Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8\/A9 as a novel possible marker for systemic sclerosis phenotype","volume":"73","author":"van Bon","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0670","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2020-000827","article-title":"Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts. BMJ Open","volume":"8","author":"Machahua","year":"2021","journal-title":"Respir Res"},{"issue":"6","key":"10.1016\/j.autrev.2023.103295_bb0675","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.resinv.2021.05.008","article-title":"Serum S100A8 and S100A9 as prognostic biomarkers in acute exacerbation of idiopathic pulmonary fibrosis","volume":"59","author":"Tanaka","year":"2021","journal-title":"Respir Investig"},{"issue":"10114","key":"10.1016\/j.autrev.2023.103295_bb0680","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2023.103295_bb0685","doi-asserted-by":"crossref","first-page":"7247238","DOI":"10.1155\/2019\/7247238","article-title":"A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease","volume":"2019","author":"Guan","year":"2019","journal-title":"J Immunol Res"},{"issue":"10","key":"10.1016\/j.autrev.2023.103295_bb0690","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1136\/gutjnl-2021-324855","article-title":"Calprotectin: from biomarker to biological function","volume":"70","author":"Jukic","year":"2021","journal-title":"Gut."},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0695","first-page":"107","article-title":"Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization","volume":"41","author":"Fukunaga","year":"2018","journal-title":"Int J Mol Med"},{"issue":"40","key":"10.1016\/j.autrev.2023.103295_bb0700","doi-asserted-by":"crossref","first-page":"11246","DOI":"10.3748\/wjg.v21.i40.11246","article-title":"Disease monitoring in inflammatory bowel disease","volume":"21","author":"Chang","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"33","key":"10.1016\/j.autrev.2023.103295_bb0705","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.3748\/wjg.v24.i33.3681","article-title":"From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting","volume":"24","author":"Mumolo","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103295_bb0710","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2739\/kurumemedj.MS664009","article-title":"Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease","volume":"66","author":"Mori","year":"2021","journal-title":"Kurume Med J"},{"issue":"12","key":"10.1016\/j.autrev.2023.103295_bb0715","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/ajg.2016.342","article-title":"Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases","volume":"111","author":"Kalla","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103295_bb0720","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/labmed\/lmz003","article-title":"Serum S100A8\/A9 as a Potentially Sensitive Biomarker for Inflammatory Bowel Disease","volume":"50","author":"Okada","year":"2019","journal-title":"Lab Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103295_bib841","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e03470","article-title":"Circulating S100A8\/A9 is potentially a biomarker that could reflect the severity of experimental colitis in rats","volume":"6","author":"Okada","year":"2020","journal-title":"Heliyon"},{"issue":"12","key":"10.1016\/j.autrev.2023.103295_bb0725","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1016\/j.crohns.2013.06.008","article-title":"Serum calprotectin as a biomarker for Crohn\u2019s disease","volume":"7","author":"Meuwis","year":"2013","journal-title":"J Crohns Colitis"},{"issue":"9","key":"10.1016\/j.autrev.2023.103295_bb0730","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/ecco-jcc\/jjac047","article-title":"A Specific Calprotectin Neo-epitope [CPa9-HNE] in Serum from Inflammatory Bowel Disease Patients Is Associated with Neutrophil Activity and Endoscopic Severity","volume":"16","author":"Mortensen","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"10","key":"10.1016\/j.autrev.2023.103295_bb0735","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2023.103295_bb0740","article-title":"Calprotectin as potential novel biomarker in myasthenia gravis","volume":"4","author":"Stascheit","year":"2021","journal-title":"J Transl Autoimmun"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2023.103295_bb0745","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0304-3940(98)00263-8","article-title":"Serum levels of macrophage-derived protein MRP-8\/14 are elevated in active multiple sclerosis","volume":"247","author":"Bogumil","year":"1998","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.autrev.2023.103295_bb0750","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.brainresbull.2018.09.014","article-title":"S100A8\/A9 induces microglia activation and promotes the apoptosis of oligodendrocyte precursor cells by activating the NF-kappaB signaling pathway","volume":"143","author":"Wu","year":"2018","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.autrev.2023.103295_bb0755","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.723009","article-title":"Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants-A Potential Novel Biomarker of Disease Activity","volume":"12","author":"Stascheit","year":"2021","journal-title":"Front Neurol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103295_bb0760","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0765","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/09273948.2018.1547835","article-title":"Proinflammatory effects of Calprotectin in Graves\u2019 Orbitopathy","volume":"28","author":"Kim","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"issue":"9863","key":"10.1016\/j.autrev.2023.103295_bb0770","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.autrev.2023.103295_bb0775","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jdermsci.2015.12.001","article-title":"Myeloid-related proteins-8 and -14 are expressed but dispensable in the pathogenesis of experimental epidermolysis bullosa acquisita and bullous pemphigoid","volume":"81","author":"Akbarzadeh","year":"2016","journal-title":"J Dermatol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0780","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/09273948.2016.1196713","article-title":"A Focus on the Epidemiology of Uveitis","volume":"26","author":"Tsirouki","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"10.1016\/j.autrev.2023.103295_bb0785","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1080\/09273948.2018.1485956","article-title":"The Expression of Calprotectin and Factors in TLR4\/NF-kappaB\/MyD88 Pathway in Patients with Idiopathic Acute Anterior Uveitis","volume":"27","author":"Song","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.autrev.2023.103295_bb0790","doi-asserted-by":"crossref","first-page":"36140","DOI":"10.1038\/srep36140","article-title":"S100A8 promotes migration and infiltration of inflammatory cells in acute anterior uveitis","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.autrev.2023.103295_bb0795","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrrheum.2017.155","article-title":"Inflammation in gout: mechanisms and therapeutic targets","volume":"13","author":"So","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0800","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13075-020-02244-6","article-title":"Neutrophil activation identifies patients with active polyarticular gout","volume":"22","author":"Vedder","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0805","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2012-202421","article-title":"Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout","volume":"73","author":"Perez-Ruiz","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2023.103295_bb0810","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3899\/jrheum.110273","article-title":"Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?","volume":"38","author":"Stamp","year":"2011","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2023.103295_bb0815","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"4 Suppl 98","key":"10.1016\/j.autrev.2023.103295_bb0820","first-page":"6","article-title":"Neutrophils and neutrophil extracellular traps orchestrate initiation and resolution of inflammation","volume":"34","author":"Hahn","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103295_bb0825","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/eji.201545605","article-title":"PMA and crystal-induced neutrophil extracellular trap formation involves RIPK1-RIPK3-MLKL signaling","volume":"46","author":"Desai","year":"2016","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103295_bb0830","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002348","article-title":"Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study","volume":"8","author":"Hammer","year":"2022","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.autrev.2023.103295_bb0835","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/art.38369","article-title":"Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout","volume":"66","author":"Holzinger","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2023.103295_bb0840","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:28:35Z","timestamp":1761600515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223000290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":170,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1568997223000290"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103295","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating Calprotectin (cCLP) in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103295"}}